2,156 material Form 8-K filings that 1,847 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
On November 9, 2026, CRH America Finance, a wholly owned subsidiary of CRH plc, completed the sale of four series of U.S. dollar guaranteed notes, fully guaranteed by CRH plc, with principal amounts totaling $4.2 billion. The company said net proceeds are expected to fund tender offers for outstanding Arcosa, Inc. notes, repay existing debt and support general corporate purposes, which adds to CRH's debt obligations while refinancing and reshaping its borrowings.
Four series issued: $1.35 billion 5.375% notes due 2032, $1.0 billion 5.625% notes due 2034, $1.35 billion 5.750% notes due 2037, and $500 million 6.250% notes due 2057
Notes were sold under an underwriting agreement dated November 4, 2026, with Barclays Capital, J.P. Morgan Securities and Morgan Stanley as representatives
Net proceeds are expected to finance tender offers for Arcosa, Inc. notes, repay existing debt and fund general corporate purposes
Innovative Industrial Properties amended its equity distribution agreements to add its 9.25% Series B Cumulative Redeemable Preferred Stock to its at-the-market offering program, alongside common stock and 9.00% Series A Preferred Stock. About $336.9 million of the program's $500 million capacity remained available as of the filing date, which gives the company a path to issue more shares that could dilute existing holders.
Program covers common stock, Series A Preferred Stock and Series B Preferred Stock, with aggregate offering price of up to $500 million
Approximately $336.9 million remained available for sale under the ATM Prospectus Supplement dated November 9, 2026
Amendments were entered into November 9, 2026 with BTIG, Piper Sandler, Roth Capital, Stifel, A.G.P./Alliance Global Partners and Huntington Securities
SS&C Technologies completed a private offering of $1.2 billion of 2.75% convertible senior notes due December 1, 2031, including a $150 million option exercised in full by the initial purchasers. The company plans to use the proceeds for capped call transactions, share repurchases of about $100 million, and redeeming its $2.0 billion of 5.500% Senior Notes due 2027, which adds debt and creates potential dilution if the notes convert.
Notes issued November 6, 2026 under an indenture with Wilmington Trust, National Association, as trustee, bearing interest at 2.75% payable June 1 and December 1.
Initial conversion price of about $99.46 per share, a premium of about 25.0% over the $79.57 closing price on November 4, 2026.
Proceeds planned for about $99 million capped call cost, about $100 million of share repurchases (about 1.3 million shares), and redemption of the $2,000.0 million 2027 Senior Notes.
Company may not redeem the notes before December 5, 2029, except in a cleanup redemption.
Jasper Therapeutics announced the results of its offer to purchase all outstanding warrants issued in its September 18, 2025 underwritten public offering, at $0.324 in cash per warrant, which expired on November 7, 2026. A total of 8,510,658 warrants were properly tendered, about 68.94% of the outstanding warrants, and the company expects to pay $2,757,453.19 in cash for them.
8,510,658 warrants were properly tendered and not withdrawn, about 68.94% of outstanding warrants.
Offer price was $0.324 in cash per warrant, without interest; the offer expired at 12:00 a.m. Eastern Time on November 7, 2026.
The company expects to pay an aggregate of $2,757,453.19 in cash, to be made promptly.
The offer was described in a Schedule TO originally filed with the SEC on October 7, 2026.
In the week of November 2 to November 8, 2026, Strategy reported $283.8 million in net proceeds from sales of its MSTR Class A common stock under its at-the-market program, and used $81.9 million of those proceeds to buy 1,036 bitcoin. It also spent $188.3 million repurchasing STRC preferred stock and held $146.2 million in USD Cash as of November 8.
MSTR common stock sales: 2,051,348 shares, $283.8 million net proceeds, with $18.3 billion still available for issuance
Bitcoin: 1,036 bitcoin bought for $81.9 million; aggregate holdings reached 850,364 bitcoin at an average purchase price of $75,456
STRC preferred repurchases: 1,887,464 shares for $188.3 million; $560.3 million remains under the preferred repurchase program
USD Reserve stood at $4.77 billion as of November 8, 2026, after $21.1 million was used for preferred dividends
Atea Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on November 6, 2026, providing for senior secured term loans of up to $200.0 million, with $65.0 million drawn at closing. The loans mature on November 1, 2031, and are secured by substantially all of the company's assets, including its intellectual property, which gives shareholders a larger fixed debt obligation tied to the company's development of BEM/RZR.
Tranche 1 loan of $65.0 million was drawn on the November 6, 2026 closing date; further tranches total up to $135.0 million
Interest floats at the greater of the WSJ prime rate plus 2.35% or 9.35%, paid monthly, with interest-only payments for 48 months
Tranche 2 availability depends on completing the Phase 3 trial of BEM/RZR before a specified date in the second half of 2027
Financial covenants include a minimum cash test beginning October 1, 2027, and a performance covenant tied to FDA approval of BEM/RZR
Precision BioSciences said it expects its November 5, 2026 share offering, along with existing cash, its at-the-market facility and continued cost discipline, to fund operations into the fourth quarter of 2029. The company projects it is sufficiently capitalized to fund its PBGENE-HBV and PBGENE-DMD clinical programs through key next-stage inflection points. The filing does not state the net proceeds amount.
Offering of 10,235,077 common shares at $7.75 per share, under an underwriting agreement dated November 5, 2026
Pre-funded warrants for up to 5,893,964 shares offered in lieu of common stock to certain investors, at $7.749995 per warrant
Expected cash runway into the fourth quarter of 2029, covering PBGENE-HBV and PBGENE-DMD programs
SBA Communications entered a $2.0 billion senior unsecured Term Loan Credit Agreement on November 6, 2026. The company intends to use the $1.165 billion of initial term loans, funded at closing, to repay its Secured Tower Revenue Securities, Series 2021-1C, while $835.0 million of delayed draw commitments remain available until May 6, 2027.
Total facility of $2.0 billion: $1.165 billion funded on November 6, 2026 and $835.0 million of delayed draw term loan commitments
Initial term loans will repay the entire $1.165 billion of Secured Tower Revenue Securities, Series 2021-1C
Term loans mature November 6, 2029, do not amortize and can be prepaid without premium or penalty
Covenants include a Consolidated Total Net Leverage Ratio not to exceed 7.50 to 1.00 and a Consolidated Senior Secured Leverage Ratio not to exceed 3.50 to 1.00
FTAI Aviation's subsidiary issued $1.0 billion of 7.125% Senior Notes due November 15, 2034, on November 6, 2026. Net proceeds will repay its revolving credit facility, which was used to fund the parent's accelerated share repurchase program, and redeem $500.0 million of 5.50% notes due 2028.
Proceeds: repay in full the Revolving Credit Facility without a reduction in commitments, redeem $500.0 million of 5.50% Senior Notes due 2028, and pay fees
Notes are senior unsecured, fully guaranteed by FTAI Aviation Ltd., and offered only to qualified institutional buyers and non-U.S. persons
Valion Bio, Inc. issued 700 Series B Preferred Shares and warrants for 21,539 common shares to investor 3i, LP for $700,000 on November 6, 2026, under a side letter to an earlier agreement. The company also agreed to register the resulting common shares for resale and extended the deadline for further closings to December 9, 2027, which may add future dilution for shareholders.
Closing purchase price: $700,000 for 700 Series B Preferred Shares and warrants
Warrants cover 21,539 shares of common stock at an initial exercise price of $0.5182 per share
Registration statement to be filed within 30 days after closing and declared effective within 60 days
Outside date for closings under the Series B Preferred Purchase Agreement extended to December 9, 2027
Mangoceuticals' sole Series B preferred holder approved terms for a new 8% Series D convertible cumulative preferred stock and an amendment to the Series B designation, which would allow the company to sell up to 1,000,000 shares at $10.00 each under Regulation A. The company said the instruments are not yet filed or effective and it may not proceed with the offering; the company also set its combined 2025 and 2026 annual meeting for December 30, 2026.
On November 2, 2026, the holder of all 50 outstanding Series B preferred shares approved the Series D terms and Series B amendment by written consent.
Proposed Series D offering: up to 1,000,000 shares at $10.00 per share under Regulation A; no sales will occur before the SEC qualifies the offering statement on Form 1-A.
Annual meeting set for December 30, 2026 in Dallas, Texas; record date is November 12, 2026.
Shareholder proposals and director nominations for the meeting are due by November 16, 2026.
BioVie Inc. agreed on November 3, 2026 to sell shares and pre-funded warrants in a registered direct offering and common warrants in a concurrent private placement, with aggregate gross proceeds of approximately $4.74 million before fees and expenses. The offering closed on November 5, 2026, and the company intends to use the net proceeds for working capital and general corporate purposes. The deal adds shares and dilutive warrants, and the company has agreed to restrictions on new share issuances.
Registered direct offering: 960,000 shares at $1.60 per share plus 2,002,500 pre-funded warrants at $1.5999 each
Concurrent private placement: 2,962,500 common warrants exercisable at $1.70 per share, starting six months after issuance
Placement agent A.G.P./Alliance Global Partners receives a cash fee of 7.0% of gross proceeds
Company and directors and officers agreed to issuance and sale restrictions for 60 days after the November 5, 2026 closing
TuHURA Biosciences borrowed an additional $1.5 million on November 2, 2026, under the revolving credit facility from its April 21, 2026 Loan Agreement with Parkview Holdings One LLC. The facility has a maximum availability of $50 million and matures on April 21, 2031, and the company says it will use the funds for general corporate purposes.
Draw of $1,500,000 received and borrowed on November 2, 2026
Revolving facility with Parkview Holdings One LLC has maximum availability of $50 million
Facility matures April 21, 2031; the Loan Agreement was originally entered into April 21, 2026
Filing notes potential conflicts of interest because the lender is an affiliate of the company's largest stockholder
Santander Holdings USA, Inc. (SHUSA) said it will redeem all 6,000 outstanding shares of its Series H Preferred Stock and the corresponding 6,000,000 depositary shares on December 15, 2026. Depositary shares will be redeemed at $25.00 each, and the redemption price excludes the regular quarterly dividend, which is payable separately on the same date to holders of record on November 30, 2026.
Redemption date: December 15, 2026, covering 6,000 preferred shares and 6,000,000 depositary shares.
Redemption price: $25.00 per depositary share, not including the declared quarterly dividend.
Quarterly dividend: $0.328125 per depositary share, payable December 15, 2026 to holders of record as of November 30, 2026.
Redemption agent: Broadridge Corporate Issuer Solutions, LLC; shares are held through DTC.
Delta Air Lines completed a public offering of $500 million in 5.500% notes maturing November 6, 2029, on November 6, 2026. The company said it will use part of the proceeds to repay about $391 million of Payroll Support Program loan borrowings, about $70 million of aircraft-secured equipment notes, and, with cash on hand, about $39 million of pass through certificates, with any remainder for general corporate purposes. The filing adds new unsecured debt to the balance sheet while reducing several existing obligations.
Notes: $500 million aggregate principal, 5.500% coupon, maturing November 6, 2029
Interest paid semi-annually on May 6 and November 6, starting May 6, 2027
Proceeds to repay about $391 million Payroll Support Program loan, about $70 million equipment notes, and about $39 million pass through certificates
American Healthcare REIT entered into a new at-the-market equity sales agreement allowing it to sell up to $1.75 billion of common stock through a group of sales agents and forward purchasers. The company terminated its prior program, which had about $170 million left unsold, and says it will use any net proceeds for general corporate purposes, which may include future investments.
Agreement allows sales of common stock with an aggregate gross sales price of up to $1,750,000,000, replacing the prior program dated February 27, 2026.
About $170,134,000 remained unsold under the prior sales agreement when it was terminated.
Agents may receive a commission of up to 2.0% of gross sales price; shares are sold under a shelf registration statement on Form S-3 dated August 12, 2024.
Proceeds would go to the Operating Partnership for general corporate purposes, which may include potential future investments.
Silgan signed a consent to its credit agreement with Wells Fargo as administrative agent, letting lenders designate a new subsidiary, Silgan Metal Packaging LLC, as an unrestricted subsidiary. The change supports the planned contribution of several container and closure businesses to that entity under the October 17, 2026 Transaction Agreement. The filing gives no financial results or deal value, so the near-term effect on shareholders is not quantified here.
Consent to Amended and Restated Credit Agreement dated November 6, 2026, with Wells Fargo Bank, National Association, as Administrative Agent
Silgan Metal Packaging LLC (MetalCo) to be designated an Unrestricted Subsidiary, releasing it as a guarantor under the credit agreement
Business Contribution tied to the Transaction Agreement dated October 17, 2026 with A-VL Holdco, LP
If the MetalCo Transactions do not close, MetalCo and its subsidiaries will cease to be Unrestricted Subsidiaries
Energy Transfer LP priced $2.7 billion of senior notes in three equal $900 million tranches, due 2032, 2037 and 2057, with coupons of 5.450%, 5.900% and 6.550%. The offering is expected to settle on November 20, 2026, and the net proceeds of about $2.68 billion (before offering expenses) are intended to refinance existing debt, including commercial paper and revolving credit facility borrowings, and for general partnership purposes.
Three $900 million tranches: 5.450% notes due 2032, 5.900% notes due 2037 and 6.550% notes due 2057.
Prices to the public were 99.972%, 99.719% and 99.862% of face value, respectively.
Expected settlement date is November 20, 2026, subject to customary closing conditions.
Net proceeds of about $2.68 billion will refinance existing indebtedness and fund general partnership purposes; several underwriters' affiliates are lenders under the revolving credit facility and may receive a share of the repayment.
Enova International said subsidiary OnDeck Asset Securitization IV, LLC intends to offer $500,251,000 of Series 2026-2 fixed rate asset-backed notes in a private securitization backed by small business loans originated or purchased by its subsidiary ODK Capital, LLC. Closing is anticipated on or about November 13, 2026, subject to market and customary conditions, so the offering may not be completed as contemplated or at all. The notes will not be obligations of or guaranteed by Enova or OnDeck, and OnDeck expects to use substantially all proceeds for loan purchases from affiliates and general corporate purposes.
Four classes total $500,251,000: Class A $190,095,000 at 5.81%, Class B $118,744,000 at 6.15%, Class C $100,050,000 at 6.73%, Class D $91,362,000 at 8.57%.
Anticipated Kroll Bond Rating Agency ratings range from AA (sf) for Class A to BB- (sf) for Class D.
Notes are offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons under Regulation S, and are not registered under the Securities Act.
Legal final payment date is December 19, 2033; the company announced the offering on November 3, 2026.
ACRES Commercial Realty Corp. entered into a Seventh Amendment to its Master Repurchase and Securities Contract Agreement with Morgan Stanley Mortgage Capital Holdings, which extends the agreement to November 2027 and modifies certain financial covenants in the related guaranty. The filing describes a routine financing amendment and does not disclose a borrowing amount, pricing, or fee figures beyond a reference to an unspecified Extension Fee.
Amendment dated November 2, 2026 extends the Morgan Stanley agreement to November 2027.
Company, as guarantor, agreed to amend certain financial covenants in its guaranty to Morgan Stanley.
Subsidiary ACRES Real Estate SPE 10, LLC is the seller; payment of an Extension Fee was due on or before November 3, 2026, amount not stated in the filing.
Zenas BioPharma filed a new prospectus supplement for an at-the-market offering of up to $200 million in common stock through Jefferies LLC, and ended the earlier program, under which it had sold about $153.2 million of shares with about $46.8 million unsold. The filing is a routine share-sale mechanism, and any sales would dilute existing shareholders, though the filing does not state whether or when any shares will be sold.
New prospectus supplement filed November 6, 2026, for up to $200,000,000 of common stock under the October 8, 2025 Sales Agreement with Jefferies LLC
Prior program terminated: about $153.2 million sold and about $46.8 million unsold at filing date
Shares to be offered under the existing Form S-3ASR registration statement, which became automatically effective upon filing
Ropes & Gray LLP legal opinion filed as Exhibit 5.1
NB Bancorp, Inc., the holding company of Needham Bank, issued $100 million of 7.50% fixed-to-floating subordinated notes due 2036 to institutional investors on November 6, 2026, at 100% of principal. The company estimates net proceeds of approximately $98,265,004.75 and plans to use them for general corporate purposes, including at least $30 million to increase the bank's Tier 1 capital, and the notes are intended to count as Tier 2 capital.
$100 million principal, maturing November 15, 2036, issued at 100% of principal in a private placement
Fixed rate of 7.50% until November 15, 2031, then resets quarterly to three-month SOFR plus 305 basis points
Estimated net proceeds of approximately $98,265,004.75; at least $30 million to be contributed to Needham Bank
Notes rated BBB- by Kroll Bond Rating Agency; Piper Sandler & Co. was sole placement agent
GATX Corporation agreed under an underwriting agreement dated November 2, 2026 to sell $300 million of 5.950% Senior Notes due 2036, and issued the notes to the underwriters on November 6, 2026. The filing describes a debt issuance rather than a change in operations, so its main significance for shareholders is the added long-term borrowing.
Principal amount: $300 million of 5.950% Senior Notes due 2036
Underwriting agreement dated November 2, 2026, with BofA Securities, Citigroup Global Markets and Morgan Stanley & Co. as representatives
Notes issued and delivered to underwriters against payment on November 6, 2026
Sold under shelf registration statement on Form S-3 (Registration No. 333-286436)
aTyr Pharma filed a prospectus supplement allowing it to sell common stock worth up to $79,994,251 from time to time under an existing open market sale agreement with Jefferies LLC. The filing sets up potential share issuance that could dilute existing shareholders, though the filing does not state how much stock has been or will be sold.
Maximum aggregate offering price of up to $79,994,251 under the Sales Agreement with Jefferies LLC, dated April 22, 2022, as amended December 23, 2024
Offering is made under Form S-3 shelf registration (File No. 333-289360), filed August 7, 2025 and declared effective August 18, 2025
Cooley LLP legal opinion on the legality of the shares filed as Exhibit 5.1
Public Storage Operating Company, a subsidiary of Public Storage, completed a $500 million offering of 5.600% Senior Notes due November 15, 2036, guaranteed by Public Storage. The filing describes new long-term unsecured debt with covenants limiting secured and unsecured borrowing and requiring unencumbered assets of at least 125% of unsecured indebtedness.
Principal amount of $500 million; interest at 5.600% per year, accruing from November 6, 2026
Interest payable semi-annually on May 15 and November 15, starting May 15, 2027; maturity November 15, 2036
Notes are unsecured and rank equally with existing and future unsecured debt of the issuer; redeemable at a make-whole price, or at 100% of principal from August 15, 2036
Offering made under a Form S-3 shelf registration; prospectus supplement dated October 29, 2026
Janus Living, Inc. closed a registered underwritten public offering of 30,187,500 Class A-1 common shares on November 6, 2026, including the underwriters' full exercise of their option to buy 3,937,500 additional shares. The filing does not state the offering price or the proceeds, and the issuance adds shares that will dilute existing holders' ownership.
Offering closed November 6, 2026 with 30,187,500 Class A-1 common shares, $0.01 par value
Underwriters exercised their option in full for 3,937,500 additional shares
Underwriting Agreement dated November 4, 2026 with BofA Securities, J.P. Morgan, Wells Fargo and Goldman Sachs as representatives
Repligen closed private exchange and subscription transactions on November 6, 2026, issuing $1.0 billion of 0.25% Convertible Senior Notes due 2031. About $541.4 million of the new notes swapped out $456.8 million of its 1.00% notes due 2028, and $458.6 million was sold for cash. The filing shows the company took on new debt with a lower coupon and a conversion price about 20% above the October 29, 2026 closing price, which could mean future share dilution if holders convert.
Issued $1.0 billion of 0.25% Convertible Senior Notes due November 1, 2031, with interest paid semi-annually starting May 1, 2027
Exchanged $456.8 million of 1.00% 2028 notes for $541.4 million of new notes; $143.2 million of 2028 notes remain outstanding
Initial conversion price of about $226.37 per share, roughly 20% above the $188.64 closing price on October 29, 2026
Up to 5,301,100 shares of common stock may be issued on conversion, including make-whole additional shares
PowerCompute entered into a Fourth Amendment to a Secured Promissory Note with Brown Family Enterprises LLC, effective October 31, 2026, extending the maturity of a $1,250,000 loan from December 31, 2026 to December 31, 2027. The filing describes a debt maturity extension only and does not state any change to the loan amount or other terms, so it defers repayment pressure by one year.
Loan principal amount: $1,250,000 from Brown Family Enterprises LLC
Maturity date extended from December 31, 2026 to December 31, 2027
Amendment dated October 31, 2026, agreement entered November 2, 2026
On November 5, 2026, EVERTEC's subsidiary Evertec Group, LLC refinanced its $387.8 million Term A loan and replaced its revolving facility under a seventh amendment to its credit agreement with Truist Bank as agent. Both facilities now mature on November 5, 2031, and revolving commitments rose from $200.0 million to $300.0 million. The company said pricing fell 25 basis points, and it paid the transaction costs with cash on hand.
Term A facility of $387.8 million refinanced through a cashless roll and now matures November 5, 2031, subject to a springing maturity tied to Term B loans.
Revolving commitments increased from $200.0 million to $300.0 million, with an additional $100 million incremental commitment fungible with the existing revolver.
Interest margins range from 1.25% to 2.25% for SOFR term loans and 0.25% to 1.25% for alternate base rate loans, based on the Total Net Leverage Ratio.
Term B loans maturing October 30, 2030 had $875 million outstanding as of November 6, 2026, and the filing says their terms are not affected.
TKO Group Holdings priced a $1.0 billion offering of 6.500% Senior Secured Notes due 2031, issued by its indirect subsidiary TKO Worldwide Holdings, LLC. The company said net proceeds may fund general corporate purposes, including distributions to parent entities to fund share repurchases under its existing program. The offering adds $1.0 billion of secured debt, which shareholders may weigh against the planned buybacks.
Pricing announced November 5, 2026: $1.0 billion aggregate principal amount of 6.500% Senior Secured Notes due 2031
Issuer is indirect subsidiary TKO Worldwide Holdings, LLC; notes guaranteed by TKO Guarantor, LLC and certain subsidiaries
Proceeds may fund share repurchases under TKO's previously announced program, plus fees and expenses
Closing expected on or about November 13, 2026, subject to customary conditions
On November 2, 2026, Public Policy Holding Company, Inc. (PPHC) entered a $105 million senior secured credit facility with Bank of America, N.A. as administrative agent, and used it to repay and terminate its existing credit agreement. The facility consists of a $65 million term loan and a $40 million revolving credit facility, maturing November 2, 2031, and the company says proceeds will also fund the Reevemark acquisition and working capital.
Facility of $105 million: a $65 million term loan and a $40 million revolving credit facility, maturing November 2, 2031
$65 million was borrowed under the term loan at closing
Interest is SOFR plus 185 to 230 basis points, set by net leverage; the company plans syndication to $150 million, expected to close January 2027 on a best-efforts basis
Existing credit agreement dated February 28, 2023 was repaid and terminated
CBRE Services, a wholly-owned subsidiary of CBRE Group, completed a $1 billion offering of senior notes in two $500 million tranches due 2032 and 2037. The Company intends to use the proceeds for general corporate purposes, including repaying commercial paper borrowings and funding the pending acquisition of Onnec Group Limited, which adds debt that shareholders will need to service.
$500 million of 5.650% Senior Notes due January 15, 2032, with semi-annual interest beginning January 15, 2027
$500 million of 5.900% Senior Notes due January 15, 2037, with semi-annual interest beginning January 15, 2027
Notes are fully and unconditionally guaranteed on a senior unsecured basis by CBRE Group, Inc.
Proceeds intended for commercial paper repayment and the pending acquisition of Onnec Group Limited
Meta Platforms completed a $15.0 billion offering of five U.S. dollar senior note series maturing from 2031 to 2056, with fixed rates from 5.850% to 7.500%. Underwriters also exercised in full their option to buy 6,000,000 additional Class A common shares from an offering priced in late October 2026, with forward sale agreements covering those shares. The filing does not state how the proceeds will be used, so the added debt and share sales are the main points for shareholders to weigh.
Five senior note series: $3.25 billion due 2031, $3.25 billion due 2033, $4.0 billion due 2036, $1.75 billion due 2046 and $2.75 billion due 2056
Notes were issued under an indenture dated August 9, 2022 with U.S. Bank Trust Company, National Association, as trustee, and a sixth supplemental indenture dated November 5, 2026
Underwriters exercised their option in full on November 4, 2026 for 6,000,000 additional Class A common shares, with additional forward sale agreements on similar terms
Underwriting agreement dated November 3, 2026 with Citigroup Global Markets Inc. and Morgan Stanley & Co. LLC as representatives
CVR Energy agreed to sell 10,515,248 common shares at $47.55 each, with net proceeds of about $490.0 million before offering expenses, closing November 5, 2026. The company plans to use the proceeds with cash on hand and other financing to fund its acquisition of the St. Paul Park and Mandan refineries from Marathon Petroleum subsidiaries, redeem its 5.750% Senior Notes due 2028, and pay related fees.
Offering: 10,515,248 shares at $47.55 per share, with a 30-day option for up to 1,577,287 additional shares
Net proceeds of approximately $490.0 million; offering closed November 5, 2026
Proceeds to fund the St. Paul Park and Mandan refinery acquisition and redeem 2028 Notes; if the acquisition does not close, proceeds go to general corporate purposes
Selling stockholder IEP Energy Holding LLC is not included in the priced offering; the company receives no proceeds from its shares
Otis Worldwide issued $500 million of 5.825% notes maturing November 5, 2036, with estimated net proceeds of about $495.3 million. The company plans to use the proceeds with cash on hand to repay its 2.293% notes due April 5, 2027, which had $500 million outstanding as of September 30, 2026. This is a routine debt refinancing that replaces near-term maturing debt with longer-dated debt at a higher stated interest rate.
Notes: $500 million principal, 5.825% annual interest, maturing November 5, 2036; interest payable May 5 and November 5 starting May 5, 2027
Estimated net proceeds of about $495.3 million, to repay 2.293% notes due April 5, 2027 ($500 million outstanding at September 30, 2026)
Notes are unsecured and rank equally with existing unsecured debt; make-whole redemption before August 5, 2036; 101% change of control put
Xometry issued a notice to redeem all approximately $85.0 million of its 1.00% Convertible Senior Notes due 2027, with redemption set for November 20, 2026, at 100% of principal plus accrued interest. Holders may still convert the notes into Class A common stock until 5:00 p.m. New York City time on November 19, 2026, and the filing says conversions after the notice will settle in physical shares. The filing is a debt-management step and gives no results or guidance figures.
Notes to be redeemed: all approximately $85.0 million aggregate principal of 1.00% Convertible Senior Notes due 2027
Redemption date: November 20, 2026, at 100% of principal plus accrued and unpaid interest from August 1, 2026
Conversion deadline: 5:00 p.m. New York City time on November 19, 2026; each $1,000 converts into 17.8213 shares, plus 0.0018 additional shares for conversions before the deadline
Live Oak Bancshares agreed on November 4, 2026 to sell 4,000,000 depositary shares, each representing a 1/40th interest in its 8.750% Series B non-cumulative perpetual preferred stock, at a $25 liquidation value per depositary share. The company expects the offering to close on or about November 12, 2026, and says the net proceeds will fund general corporate purposes, including balance sheet growth at Live Oak Banking Company and its capital position.
Underwriters are Morgan Stanley & Co. LLC, Keefe, Bruyette & Woods, RBC Capital Markets and UBS; the underwriters have a 30-day option for up to 600,000 additional depositary shares.
Dividends are 8.750% per annum, payable quarterly when declared by the board, beginning December 15, 2026.
The company may redeem the Series B preferred stock on or after December 15, 2031, or after a regulatory capital treatment event, at $1,000 per share ($25 per depositary share).
Live Oak intends to list the depositary shares on the NYSE under the symbol LOB/PB.
Xcel Energy issued $2.5 billion of 2.625% convertible senior notes due December 15, 2027, including $300 million from the initial purchasers' option. The notes are convertible into Xcel common stock at an initial conversion price of about $87.26 per share, and conversions can be settled in cash, shares, or a mix. Because the notes are convertible, they could add up to 31,513,750 shares of common stock to the share count if holders convert at the maximum rate.
Issued $2,500,000,000 of 2.625% Convertible Senior Notes due December 15, 2027, dated November 5, 2026
Initial conversion rate of 11.4596 shares per $1,000 principal, or about $87.26 per share
Up to 31,513,750 shares may be issued on conversion at the initial maximum conversion rate of 12.6055 shares per $1,000
Notes cannot be redeemed by Xcel Energy before maturity and carry no sinking fund
Enova International priced a private offering of $600 million in senior notes due 2031 at par, bearing 8.750% annual interest, with closing expected November 20, 2026. The company plans to use the proceeds to redeem all of its 11.25% senior notes due 2028 on December 15, 2026, pay offering fees, and repay part of its revolving credit facility borrowings, which refinances higher-rate debt for shareholders to watch.
Offering size: $600 million aggregate principal amount of senior notes due 2031, priced at 100.000% of principal
Interest rate: 8.750% per annum; notes are senior unsecured and guaranteed by domestic subsidiaries
Expected closing: November 20, 2026, subject to customary conditions
Use of proceeds: redeem all 11.25% senior notes due 2028 on December 15, 2026, and repay part of revolver borrowings
HCA Inc., a wholly owned subsidiary of HCA Healthcare, completed on November 5, 2026 a public offering of $6.5 billion of senior unsecured notes in seven series maturing from 2028 to 2056, fully guaranteed by HCA Healthcare. The filing does not state how the proceeds will be used, but the offering adds $6.5 billion of debt obligations for the company.
Seven series totaling $6.5 billion; the largest is $1.5 billion of 6.000% senior notes due November 15, 2036.
Fixed-rate coupons range from 5.200% to 6.500%, and $300 million of floating-rate notes mature November 3, 2028.
Underwriting agreement dated November 2, 2026 with Mizuho Securities USA LLC, Barclays Capital Inc., BofA Securities, Inc. and Wells Fargo Securities, LLC as representatives.
Holders can require repurchase at 101% of principal only upon both a qualifying ratings downgrade and a change of control.
TD SYNNEX entered into a $1,750 million senior unsecured term loan with Bank of America as administrative agent, dated November 2, 2026. Part of the proceeds repaid in full an existing $750 million term loan that would have matured September 1, 2027, and the rest will fund general corporate purposes, including acquisitions.
New term loan: $1,750 million, maturing November 2, 2029, with no scheduled amortization before maturity
Interest set at SOFR plus a margin of 1.00% to 1.625%, based on TD SYNNEX's public debt rating
Repaid in full the $750 million term loan that would have matured September 1, 2027
Financial covenants require a maximum funded debt to EBITDA ratio of 4.00 to 1.00 and a minimum EBITDA to interest charges ratio of 3.00 to 1.00
Aeries Technology disclosed a settlement agreement dated October 30, 2026, with Sea Otter Trading, LLC over obligations under a forward purchase agreement. The company agreed to pay $911,461 through an escrow arrangement in exchange for the return of 145,183 Class A ordinary shares held as collateral, and mutual general releases will take effect once the share transfer and payment are completed. The filing does not disclose the company's financial results, and it replaces the earlier letter agreement terms that had been disclosed August 3, 2026.
Settlement agreement dated October 30, 2026, with Sea Otter Trading, LLC
Company to pay $911,461 through escrow to recover 145,183 collateral Class A ordinary shares
Mutual general releases and termination of the Letter Agreement take effect upon completion of the share transfer and payment
Fate Therapeutics entered a Sales Agreement with Leerink Partners for an at-the-market program allowing it to sell up to $100 million of common stock at its discretion, and terminated its earlier $100 million program with Jefferies. The company has already sold 2,801,602 shares for $8.0 million under the Jefferies program. The new program could add shares outstanding and dilute existing shareholders if the company chooses to sell.
Leerink Partners may sell up to $100,000,000 of common stock; the company pays a commission of up to 3.0% of gross proceeds.
The Jefferies program was terminated on November 5, 2026, with no termination penalties, after sales of 2,801,602 shares for $8.0 million.
The existing Form S-3 expires November 27, 2026; the company plans to file a new registration statement, and may sell under the existing one until the earlier of the new registration's effectiveness and May 26, 2027.
Alphabet closed an underwritten public offering of €6 billion in euro-denominated senior notes on November 5, 2026, issued under an indenture dated February 12, 2016. The notes come in seven tranches maturing between 2028 and 2045, which adds to the company's long-term debt.
Total offering of €6 billion across seven tranches, maturing 2028 to 2045
Largest tranches are €1.25 billion of 4.050% notes due 2030 and €1 billion of 5.250% notes due 2045
Issued under a registration statement on Form S-3 and an indenture with The Bank of New York Mellon Trust Company, N.A., as trustee
Brixmor's operating partnership signed a $400 million delayed-draw term loan facility, undrawn as of November 5, 2026, and amended its existing revolving credit and term loan agreements to lower borrowing rates and facility fees. The filing describes financing terms rather than a reported change in earnings, and the facility is not yet drawn.
$400 million delayed-draw term loan facility with Wells Fargo, drawable within six months and maturing February 15, 2031
Revolver amendment with JPMorgan Chase lowers term SOFR margins to 0.65% to 1.35% and facility fees to 0.10% to 0.30%
Term loan amendment lowers term SOFR margins to 0.70% to 1.55%, with pricing tied to credit rating
Aimei Health Technology Co., Ltd. deposited $34,330.96 into its trust account to extend the deadline to complete its initial business combination by one month, from November 6, 2026 to December 6, 2026. The company funded the payment with an unsecured, non-interest-bearing promissory note to Aimei Investment Ltd, which becomes due only at the business combination, so the extension adds to the company's obligations for public shareholders.
Extension Payment of $34,330.96 is the lesser of $80,000 or $0.033 per outstanding public share for each monthly extension.
Termination date moves from November 6, 2026 to December 6, 2026; the filing describes this as the twenty-fourth extension.
Promissory note dated November 5, 2026, issued to Aimei Investment Ltd, is convertible at the payee's option into private units at $10.00 per unit.
On October 29, 2026, Cycurion entered into agreements giving Obsidian Associates, LLC and M2B Funding Corp. a limited right to exchange their Series H Convertible Preferred Stock, plus accrued and unpaid dividends, for common stock at $2.70 per share, subject to a possible Nasdaq Minimum Price adjustment. Upon exchange, the preferred shares are cancelled and the holders receive only common stockholder rights on the new shares, so existing common shareholders may face dilution, though the filing does not state the number of common shares to be issued.
Holders: Obsidian Associates, LLC (618.75 Series H shares) and M2B Funding Corp. (952.70 Series H shares), plus accrued dividends
Exchange price of $2.70 per common share, subject to adjustment to the Nasdaq Minimum Price if applicable
Exchange window opens after the Company files a Listing of Additional Shares notice with Nasdaq and publicly discloses the transactions
Agreements include a 4.99% beneficial ownership limit and a resale limit of 5.0% of average daily trading volume over the prior ten trading days
Prospect Capital Corporation closed a $300 million offering of 8.95% senior unsecured notes due October 31, 2031 on November 5, 2026, issued under a registered direct offering. The Company expects net proceeds of about $283.4 million, mainly to refinance existing debt, including repaying its 3.364% Notes due 2026 and/or revolver borrowings.
Principal: $300 million of 8.95% Notes due October 31, 2031, with interest paid semi-annually on April 30 and October 31, starting April 30, 2027
Expected net proceeds: approximately $283.4 million after estimated offering expenses
Use of proceeds: primarily refinancing, including repayment of the 3.364% Notes due 2026 and/or revolving credit facility borrowings
Optional redemption at par plus a make-whole premium before April 30, 2029; holders may require repurchase at par plus accrued interest upon a Change of Control Repurchase Event
L3Harris closed the sale of $1.0 billion of senior notes on November 5, 2026, split into $500 million due 2029 at 5.200% and $500 million due 2032 at 5.400%. The company plans to use the proceeds for general corporate purposes, including repaying $550 million of 3.85% notes due December 15, 2026 and helping fund part of the $1,250 million 5.40% notes due January 15, 2027.
$1.0 billion total: $500 million of 5.200% notes due 2029 and $500 million of 5.400% notes due 2032
Proceeds earmarked for the $550 million 3.85% notes maturing December 15, 2026
Proceeds, with cash on hand, to partly fund the $1,250 million 5.40% notes maturing January 15, 2027
Kartoon Studios said its sponsored subsidiary, Kartoon Studios Acquisition Corp. (KSAC), filed a Form S-1 registration statement for a proposed $300 million initial public offering of units. The registration statement has not yet become effective, and the units cannot be sold until it does. KSAC intends to pursue media and entertainment business combinations, and the company said there is no assurance the filing will result in any transaction.
Proposed offering of 30,000,000 units at $10.00 per unit, for gross proceeds of $300.0 million, plus an underwriter option for up to an additional 15% of units
Each unit consists of one Class A ordinary share and one redeemable warrant; KSAC intends to list the units on the New York Stock Exchange under the symbol 'KACQ U'
E.F. Hutton & Co. is sole underwriter and book-running manager; Kartoon owns 100% of the sponsor, Toon Acquisition LLC
Andy Heyward, Brian Parisi and Michael Jaffa will lead KSAC, and the filing was announced on November 5, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.